After consultation with the company's largest shareholders in terms of votes, as of
Sarah Fredriksson , appointed byAQILION AB -
Thomas Nestenius, appointed by
Zoya Invest AB
The annual general meeting will be held on
For more information, please contact:
Ebba Fåhraeus, chairman of the board, telephone; 073 400 04 33, ebba@smileincubator.life
The information was submitted for publication, through the agency of the contact person above, on
About
AcuCort AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need 2 supplemental oxygen therapy . Zeqmelit® is approved in
https://news.cision.com/acucort-ab/r/acucort-appoints-nomination-committee,c3714030
https://mb.cision.com/Main/15601/3714030/1845281.pdf
(c) 2023 Cision. All rights reserved., source